Back

Teva announces olanzapine LAI data showing stabilization and long-term efficacy

Verifying
  • Teva announced post hoc data for its new olanzapine LAI, TEV-'749.
  • TEV-'749 showed high rates of stabilization and long-term efficacy.
  • The once-monthly subcutaneous injectable is intended for adults with schizophrenia.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.